Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 9/20 | 0.61 |
| ▸ | HTR1A | P08908 | 8/20 | 0.61 |
| ▸ | HTR2C | P28335 | 8/20 | 0.61 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | HTR1B | P28222 | 7/20 | 0.61 |
| ▸ | HTR2B | P41595 | 6/20 | 0.61 |
| ▸ | HTR6 | P50406 | 6/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.61 |
| ▸ | HTR3B | O95264 | 4/20 | 0.61 |
| ▸ | HTR1E | P28566 | 4/20 | 0.61 |
| ▸ | HTR1F | P30939 | 4/20 | 0.61 |
| ▸ | HTR7 | P34969 | 4/20 | 0.61 |
| ▸ | HTR3A | P46098 | 4/20 | 0.61 |
| ▸ | HTR5A | P47898 | 4/20 | 0.61 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27517077 | 0.83 | CSNK2A1 (0.56) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL15701965 | 0.81 | HTR1D (0.63) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL18824168 | 0.81 | HTR2A (0.68) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL517473 | 0.81 | SLC6A4 (0.83) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL29471382 | 0.81 | SLC6A4 (0.83) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL25747532 | 0.80 | HTR1A (0.74) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL30483734 | 0.80 | HTR1A (0.74) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL31377418 | 0.78 | HTR1A (0.79) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL26602823 | 0.78 | HTR1A (0.79) | HTR1DHTR1AHTR2CHTR2AHTR1B | |
| SCHEMBL3190334 | 0.77 | HTR2A (0.65) | HTR1DHTR1AHTR2CHTR2AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | HAMANN MARK T (US) | 2012-02-02 | — | — | US | claimed |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | HAMANN, MARK T. | 2009-04-09 | — | — | US | claimed |
| US-8268856-B2 | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter | HAMANN MARK T (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | HAMANN MARK T (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2209380-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | Triton Biopharma, Llc (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049030-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | TRITON BIOPHARMA, LLC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | HAMANN, MARK T. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029010-A1 | METHOD TO USE COMPOSITIONS HAVING ANTIDEPRESSANT ANXIOLYTIC AND OTHER NEUROLOGICAL ACTIVITY AND COMPOSITIONS OF MATTER | ACHE, CHAT, HTR3D | HTR1D 48/4885HTR1A 16/4885HTR2C 117/4885 |
| US-20090093513-A1 | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter | ACHE, CHAT, HTR3D | HTR1D 48/4885HTR1A 16/4885HTR2C 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.